ArticleHistochemistry and cell biology2015
Supremacy of modern morphometry in typing renal oncocytoma and malignant look-alikes.
Article in Histochemistry and cell biology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 15 citations in OpenAlex.
- Evaluating the clinical significance of tumor-expressed C-reactive protein in chromophobe renal cell carcinoma.Scientific reports · 2026Article
- Article
- Immunohistochemical expression of the hepatocyte growth factor in chromophobe renal cell carcinoma.BMC urology · 2023Article
- The synergism of spatial metabolomics and morphometry improves machine learning-based renal tumour subtype classification.Clinical and translational medicine · 2022Article
- Article
- In Situ Metabolomics Expands the Spectrum of Renal Tumours Positive onEuropean urology open science · 2020Article
- [Chromophobe renal cell carcinoma-diagnosis and prognosis].Der Pathologe · 2019Review
- Comparison of isolation platforms for detection of circulating renal cell carcinoma cells.Oncotarget · 2017Article
- PD-L2: A prognostic marker in chromophobe renal cell carcinoma?Medical oncology (Northwood, London, England) · 2017Article
- c-Met in chromophobe renal cell carcinoma.Medical oncology (Northwood, London, England) · 2017Article
- [Oncocytoma versus chromophobe renal cell carcinoma: Is there something in between?].Der Pathologe · 2016Review
- The Histochemistry and Cell Biology omnium-gatherum: the year 2015 in review.Histochemistry and cell biology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the era of tumour type-specific therapies, the correct typing of renal tumours is of prime importance. As immunotyping and genotyping approaches are laborious and fall short of standardization, we used whole-scale computer-assisted morphometry instead. Three different types of renal tumours with different prognoses and therapies, notoriously prone to mistyping, were analysed . The sample of 335 tumours included clear cell renal cell carcinoma, chromophobe renal cell carcinoma and renal oncocytoma. The sample was analysed using H&E stains of tissue microarrrays in combination with an image-scanning software. Nuclear and cytoplasmic features were registered with the aid of computer-assisted morphometry. Features included shape, texture, colour and colour intensity for different cell compartments, e.g. nuclei and cytoplasm. The software passed several training steps for final validation. Using morphometry, we were able to classify the three renal tumour types correctly, with a 100 % specificity compared to the WHO typing. Nuclear features dominated the typing of chromophobe renal cell carcinoma, whereas cytoplasmic features were the leading classificators for renal oncocytoma. The grading of clear cell renal cell carcinoma attained a specificity of 80 %. In conclusion, modern morphometry may serve as a tool for typing renal epithelial tumours and additionally draws the attention to future nuclear research in chromophobe renal cell carcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.